STRATA Skin Sciences, Inc.: insider trades · United States · SEC (Form 4)

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences, Inc. is a U.S. medical technology company focused on dermatology and listed on the NASDAQ market in the United States. Headquartered in Horsham, Pennsylvania, the company serves dermatologists and their patients with targeted treatment platforms for chronic skin conditions. Its profile is that of a niche med-tech player rather than a broad pharmaceutical company, with a business model that combines equipment sales and recurring revenue from utilization of its installed base. The company has evolved around excimer laser technology and later sharpened its focus through portfolio reshaping and acquisitions. STRATA moved away from its former MelaFind initiative and changed its name in 2016. Today, its core commercial offerings include the XTRAC® and Pharos® excimer lasers and the VTRAC® lamp system, which are used in the treatment of psoriasis, vitiligo, and other inflammatory or autoimmune dermatologic disorders. In 2022, STRATA broadened its strategy with the acquisition of the TheraClear® Acne Therapy System, marketed as TheraClear® X, giving the company exposure to the acne treatment market as well. From a competitive standpoint, STRATA differentiates itself through highly targeted UVB-light treatment technologies aimed at large but often under-served dermatology indications. The company reports an installed base of systems in dermatology offices, primarily in the United States, alongside a smaller but growing international footprint. Its economics are driven by recurring procedure revenue, which can provide more stability than an equipment-only model. Recent developments suggest a company still in an operational rebuilding and expansion phase. In 2025, STRATA reported modest quarterly revenue growth, continued international momentum, and progress on expanding CPT reimbursement codes for inflammatory and autoimmune skin diseases in the United States, potentially increasing the addressable market. The company also obtained Mexican regulatory clearance for TheraClearX and began first commercial placements there. At the same time, recent SEC filings show that the common stock was delisted from the Nasdaq Capital Market as of February 19, 2026 and is now quoted over the counter (OTC), which is a material consideration for investors assessing liquidity and financing risk. For French, Belgian, and Swiss investors, STRATA is therefore a U.S. healthcare small cap with exposure to both clinical adoption and reimbursement expansion. The equity should be viewed as a higher-risk, higher-volatility med-tech name, with progress dependent on commercialization execution, payer coverage expansion, and balance-sheet support.